IN SILICO STUDY OF PHYSALIS ANGULATA COMPOUNDS AS POTENTIAL THERAPEUTICS FOR ECZEMATIC SKIN DISEASES

Yan Martin Witantra

doi:10.5281/zenodo.21322464

Authors

Yan Martin Witantra Universitas Pertahanan Republik Indonesia

DOI:

https://doi.org/10.5281/zenodo.21322464

Keywords:

eczematic, withangulain B, physagulin C, and withanolide, IL-4Rα receptor, IL-13Rα1 receptor, molecular docking

Abstract

Eczema, a broad term encompassing a number of chronic inflammatory skin disorders, is typically characterized by symptoms such as redness (erythema), itching (pruritus), dryness, thickening of the skin due to repeated scratching (lichenification), and the possible appearance of fluid (exudation) or small blisters (vesicles). IL-4 and IL-13 activate the JAK-STAT pathway through the IL-4Rα and IL-13Rα1 receptors, which promotes STAT6 activation and the inflammatory response in atopic dermatitis, thus providing the basis for the use of upadacitinib as a selective JAK1 inhibitor that is effective in alleviating the symptoms of the disease. The aim of this study was to explore potential therapeutic pathways, with particular attention to compounds present in Physalis angulata , including the withanolide group such as withangulain B, physagulin C, and withanolide, which is one of 41 groups of compounds that have been identified in Physalis angulata . In addition, this study also evaluated the control drug upadacitinib, which is designed to target the IL-4Rα and IL-13Rα1 receptors, which play a key role in the type 2 (Th2) immune response. The study utilized several computational techniques, including data mining, biological activity analysis, ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) profiling, molecular mapping, and in silico studies. The results showed that the binding energies of the ligands (Physagulin C and Withangulatin B) with the IL-4Rα receptor were -12.6 kcal/mol and -12.7 kcal/mol, respectively. Similarly, Withanolide and Withagulatin B were identified as the top candidate compounds for the IL-13Rα1 receptor, with binding energies of -11.5 and -11.5 kcal/mol, respectively. The interactions above are the most beneficial for the development of eczematic disease therapy. The overall results of this study demonstrate great potential, indicating that the withanolide compounds, physagulin c, and withangulatin B derived from Physalis angulata offer an alternative pathway in targeting immune cells (Th2) through JAK-STAT activation and STAT6 translocation to the nucleus. Therefore, this study opens up opportunities for the development of innovative therapies in the treatment of eczematic diseases.

Downloads

Download data is not yet available.

References

Bieber, T. (2008). Atopic Dermatitis. In N Engl J Med (Vol. 358). www.nejm.org

Boguniewicz, M., & Leung, D. Y. M. (2010). Recent insights into atopic dermatitis and implications for management of infectious complications. Journal of Allergy and Clinical Immunology, 125(1), 4–13. https://doi.org/10.1016/j.jaci.2009.11.027

Deckers, I. A. G., McLean, S., Linssen, S., Mommers, M., van Schayck, C. P., & Sheikh, A. (2012). Investigating international time trends in the incidence and prevalence of atopic eczema 1990-2010: A systematic review of epidemiological studies. In PLoS ONE (Vol. 7, Number 7). https://doi.org/10.1371/journal.pone.0039803

Fadhli, H., Ruska, S. L., Furi, M., Suhery, W. N., Susanti, E., & Nasution, M. R. (2023). Ciplukan (Physalis angulata L.): Review Tanaman Liar yang Berpotensi Sebagai Tanaman Obat. JFIOnline | Print ISSN 1412-1107 | e-ISSN 2355-696X, 15(2), 134–141. https://doi.org/10.35617/jfionline.v15i2.144

Fitrianingsih, S. P., Kurniati, N. F., Fakih, T. M., & Adnyana, I. K. (2025). Integrating network pharmacology, molecular docking, and molecular dynamics to explore the antidiabetic mechanism of Physalis angulata L. Pharmacia, 72, 1–29. https://doi.org/10.3897/pharmacia.72.e149156

Global Burden of Disease Study (GBD). (2021). GBD_2021_Booklet_FINAL_2024.05.16.

Guttman‐Yassky, E., Krueger, J. G., & Lebwohl, M. G. (2018). Systemic immune mechanisms in atopic dermatitis and psoriasis with implications for treatment. Experimental Dermatology, 27(4), 409–417. https://doi.org/10.1111/exd.13336

Guttman-Yassky, E., Teixeira, H. D., Simpson, E. L., Papp, K. A., Pangan, A. L., Blauvelt, A., Thaçi, D., Chu, C.-Y., Hong, H. C., Katoh, N., Paller, A. S., Calimlim, B., Gu, Y., Hu, X., Liu, M., Yang, Y., Liu, J., Tenorio, A. R., Chu, A. D., & Irvine, A. D. (2021). Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. The Lancet, 397(10290), 2151–2168. https://doi.org/10.1016/S0140-6736(21)00588-2

Indradi, R. B., Muhaimin, M., Barliana, M. I., Khatib, A., Maisyarah, I. T., Pitaloka, D. A. E., & Pratomo, M. F. (2025). Multi-target mechanism of Physalis angulata to treat malaria based on network pharmacology and molecular docking. Journal of Herbal Medicine, 51, 101021. https://doi.org/10.1016/j.hermed.2025.101021

Jonsen Subagio. (2024). Herbal Monographs and Role of Physalis angulata in Indigenous Herbal Systems: A Literature Review.

Karimkhani, C., Dellavalle, R. P., Coffeng, L. E., Flohr, C., Hay, R. J., Langan, S. M., Nsoesie, E. O., Ferrari, A. J., Erskine, H. E., Silverberg, J. I., Vos, T., & Naghavi, M. (2017). Global skin disease morbidity and mortality an update from the global burden of disease study 2013. JAMA Dermatology, 153(5), 406–412. https://doi.org/10.1001/jamadermatol.2016.5538

LaPorte, S. L., Juo, Z. S., Vaclavikova, J., Colf, L. A., Qi, X., Heller, N. M., Keegan, A. D., & Garcia, K. C. (2008). Molecular and Structural Basis of Cytokine Receptor Pleiotropy in the Interleukin-4/13 System. Cell, 132(2), 259–272. https://doi.org/10.1016/j.cell.2007.12.030

Lionta, E., Spyrou, G., Vassilatis, D. K., & Cournia, Z. (2014). Structure-Based Virtual Screening for Drug Discovery: Principles, Applications and Recent Advances. In Current Topics in Medicinal Chemistry (Vol. 14).

Meng, X.-Y., Zhang, H.-X., Mezei, M., & Cui, M. (2011). Molecular Docking: A Powerful Approach for Structure-Based Drug Discovery. In Current Computer-Aided Drug Design (Vol. 7).

Nelms, K., Keegan, A. D., Zamorano, J., Ryan, J. J., & Paul, W. E. (1999). THE IL-4 RECEPTOR: Signaling Mechanisms and Biologic Functions. In Annu. Rev. Immunol (Vol. 17). www.annualreviews.org

Nutten, S. (2015). Atopic Dermatitis: Global Epidemiology and Risk Factors. Annals of Nutrition and Metabolism, 66(Suppl. 1), 8–16. https://doi.org/10.1159/000370220

Rengifo-Salgado, E., & Vargas-Arana, G. (2013). © 2013 Boletín Latinoamericano y del Caribe de Plantas Medicinales y Aromáticas 12 (5): 431-445 ISSN 0717 7917 Physalis angulata L. (Bolsa Mullaca): A Review of its Traditional Uses, Chemistry and Pharmacology [Physalis angulata L. (Bolsa Mullaca): Revisión de Usos Tradicionales, Química y Farmacología]. www.blacpma.usach.cl

Rerknimitr, P., Otsuka, A., Nakashima, C., & Kabashima, K. (2017). The etiopathogenesis of atopic dermatitis: Barrier disruption, immunological derangement, and pruritus. In Inflammation and Regeneration (Vol. 37, Number 1). BioMed Central Ltd. https://doi.org/10.1186/s41232-017-0044-7

RISKESDAS. (2010). RISET KESEHATAN DASAR RISKESDAS 2010.

Sainah, N., Fahdhienie, F., Septiani, R., Kesehatan, F., & Muhammadiyah Aceh, U. (2024). FAKTOR-FAKTOR YANG BERHUBUNGAN DENGAN KEJADIAN DERMATITIS KONTAK ALERGI PADA USIA 15-44 TAHUN DI PUSKESMAS BATOH KOTA BANDA ACEH.

Silverberg, J. I., & Hanifin, J. M. (2013). Adult eczema prevalence and associations with asthma and other health and demographic factors: A US population–based study. Journal of Allergy and Clinical Immunology, 132(5), 1132–1138. https://doi.org/10.1016/j.jaci.2013.08.031